The Pharma Data

JUNE 26, 2021

Early in the COVID-19 pandemic, scientists identified how SARS-CoV-2, the virus that causes COVID-19, gets inside cells to cause infection. All current COVID-19 vaccines and antibody-based therapeutics were designed to disrupt this route into cells, which requires a receptor called ACE2. The study is published June 23 in Cell Reports.

Virus 52

Virus Cell Biology Vaccine Research 52

PerkinElmer

APRIL 21, 2020

Although the novel coronavirus is the subject of nearly every media story right now, several years ago it was the Zika virus (ZIKV) gathering a great deal of attention. There are currently no targeted therapeutics for its treatment, nor is there an existing vaccine.

Virus 52

Virus FDA Approval Laboratories Vaccine 52

Broad Institute

MAY 14, 2024

William Studier for development of widely used protein- and RNA-production platform The $400,000 award recognizes the far-reaching medical impacts of Studier’s development, in the 1980s, of an efficient and scalable technology to produce mass amounts of RNA and proteins in laboratories that is widely used today all over the world.

RNA 84

RNA Production Molecular Biology Laboratories 84

The Pharma Data

DECEMBER 2, 2020

The License provides EYAM with the exclusive right to develop several proprietary COVID-19 vaccine candidates in a self-amplifying mRNA vaccine platform. EYAM anticipates rapid commencement of animal trials for these COVID-19 vaccine candidates. This License Agreement represents an important corporate milestone.

Licensing 52

Licensing Licensing Vaccine Virus 52

The Pharma Data

MARCH 14, 2021

Following a recent concern raised around thrombotic events, AstraZeneca would like to offer its reassurance on the safety of its COVID-19 vaccine based on clear scientific evidence. Safety is of paramount importance and the Company is continually monitoring the safety of its vaccine. COVID-19 Vaccine AstraZeneca , formerly AZD1222.

Vaccine 52

Vaccine Virus Licensing Licensing 52

SCIENMAG: Medicine & Health

OCTOBER 18, 2023

This study is conducted by the Jiangsu Provincial Center for Disease Control and Prevention, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, State Key Laboratory of Vaccines for Infectious Diseases of Xiamen University, China National Institutes for Food and Drug Control, and Xiamen Innovax Biotech Company.

Vaccine 52

Vaccine Laboratories Virus Science 52

The Pharma Data

AUGUST 3, 2021

The drug, which has undergone several clinical trials for human conditions but has not yet received approval to treat humans, inhibited the replication of SARS-CoV-2, the virus that causes COVID-19, in human cell cultures and in a mouse model, leading to much lower viral loads. The research team, including scientists from the U.S.

Virus 52

Virus Clinical Trials Drugs Laboratories 52

The Pharma Data

MARCH 25, 2021

European Medicines Agency to Conduct First-Ever Parallel Assessment of a Medicinal Product, Takeda’s Dengue Vaccine Candidate (TAK-003), for use in the EU; Countries Outside of the EU through the EU-M4all (Previously Article 58) Procedure. About TAK-003. 4,5 Efficacy varied by serotype.

Vaccine 52

Vaccine Virus Trials Hospitals 52

The Pharma Data

SEPTEMBER 18, 2020

This week Pharma IQ looks at how the pharma industry is expanding its vaccine manufacturing and testing protocols to ensure the deadly Covid-19 outbreak yields in its spread around the globe. . BioNTech acquires Novartis GMP manufacturing site to expand Covid-19 vaccine production. Vivera Pharmaceuticals, Inc.

Vaccine 52

Vaccine Long-Term Care Facilities Clinical Supply Laboratories 52

The Pharma Data

FEBRUARY 23, 2022

* Final analysis of the global VAT02 booster trial confirms universal ability to boost neutralizing antibodies 18- to 30-fold across vaccine platforms (mRNA, adenovirus). * efficacy against any symptomatic COVID-19 disease, in line with expected vaccine effectiveness in today’s environment dominated by variants of concern.

Vaccine 52

Vaccine Virus Trials Immune Response 52

The Pharma Data

SEPTEMBER 17, 2020

The new Elecsys Anti-SARS-CoV-2 S test can quantitatively measure the level of antibodies against SARS-CoV-2 in patients who have been exposed to the virus. This is the focus of vaccines in development and convalescent plasma therapy. The test targets antibodies against the spike protein. said Thomas Schinecker, CEO Roche Diagnostics.

Vaccine 52

Vaccine Virus Clinical Trials Immune Response 52

The Pharma Data

APRIL 22, 2023

The current COVID-19 vaccines are designed to trigger an antibody response to the SARS-CoV-2 spike protein, which is vulnerable to mutations that could make the vaccine less effective over time. of the mice that were vaccinated with the T-cell-based vaccine survived, while only one of the control-group mice survived.

Vaccine 40

Vaccine Virus Laboratories Immune Response 40

Broad Institute

JANUARY 30, 2024

He has also emerged in recent years as a skilled and relatable science communicator, renowned for his efforts at Broad and beyond during the COVID-19 pandemic to unpack the fast-moving research on the new virus in an accessible way and give practical advice about masking, vaccines, and other public health measures.

Hospitals 137

Hospitals Medical Schools Virus Science 137

Codon

DECEMBER 12, 2024

Some scientists even think it had a virus defense system; “researchers say LUCA likely housed 19 CRISPR genes, which bacteria use to slice up viral threats,” reports Quanta Magazine. A mirrored organism would use right-handed molecules everywhere a naturally-occurring organism uses left-handed ones, and vice versa.

DNA 100

DNA RNA Vaccine Virus 100

Codon

AUGUST 27, 2024

While reading all the sequences present in a sample, researchers want to find any that are out of place, such as those that belong to a never-before-seen virus. New Yorkers wait to receive a monkeypox vaccine. At least nine laboratories outside the U.S. The city has had hundreds of positive cases in 2024.

DNA 86

DNA Laboratories Hospitals Virus 86

Drug Target Review

DECEMBER 6, 2023

Chapter 2 explores immuno-oncology, emphasising the significance of robust T cells, the potential of cytokines IL-12 and IL-18, and the innovative use of CAR T-cell methods against the SARS-CoV-2 virus. Join us as we navigate the forefront of cancer research, offering first hand insights into transformative breakthroughs.

Research 64

Research Pharmacy Vaccine Laboratories 64

The Pharma Data

JUNE 1, 2022

has been appointed Senior Vice President and Head of the Company’s Vaccine Research & Development (R&D) organization effective August 1, succeeding Kathrin U. Annaliesa is a world-class scientist with a track record of delivering both vaccines and therapeutics in pioneering new areas of science and where there is urgent unmet need.

Vaccine 40

Vaccine Research Laboratories Doctors 40

The Pharma Data

JANUARY 26, 2021

offered its genomics expertise to identify emerging variants of the SARS-CoV-2 virus to countries that lack the resources to make such identifications. The plan dovetails with the Chatham House Sustainable Laboratories Initiative , announced in 2019. On Tuesday, the U.K. The offer came as part of the U.K.’s South Africa and Brazil.

Virus 52

Virus Vaccine Laboratories International 52

The Pharma Data

JANUARY 13, 2021

13, 2021 — A single-shot COVID-19 vaccine from Johnson & Johnson has shown very strong results in early clinical trials, potentially providing a significant boost to U.S. vaccination efforts. The new vaccine remains stable for a time in the refrigerator. WEDNESDAY, Jan. 13 in the New England Journal of Medicine.

Vaccine 40

Vaccine Trials Clinical Trials Immune Response 40

The Pharma Data

AUGUST 16, 2020

Dr James Hindley says T cells can create more antibodies if a person is exposed to the virus again. A company in Cardiff has developed a test for coronavirus T cells – which can potentially provide longer-term immunity to the virus than antibodies. “That’s the basis of vaccination and vaccination development.

Virus 52

Virus Vaccine Immune Response Government 52

NIH Director's Blog: Drug Development

MAY 21, 2020

B38 blocks SARS-CoV-2 from binding to the ACE2 receptor (light pink) of a human cell, ACE2 is what the virus uses to infect cells. The research team, led by Yan Wu, Capital Medical University, Beijing, first isolated the pair of antibodies in the laboratory, starting with white blood cells from the patient. In the U.S.

Virus 52

Virus Vaccine Laboratories Small Molecule 52

The Pharma Data

NOVEMBER 26, 2020

Researchers at Heidelberg University in Germany performed detailed imaging analysis to determine how SARS-CoV-2, the virus that causes COVID-19, reprograms infected cells. The virus causes changes in the membrane so it can produce its own replication organelles, amplifying the viral genome. It only takes 24 to 48 hours.

Research 52

Research Virus Vaccine DNA 52

The Pharma Data

JANUARY 26, 2021

In what looks like a breakthrough for COVID-19 treatments, Regeneron’s monoclonal antibody cocktail REGEN-COV (casirivimab and imdevimab) cut infection rates in half and provided full protection against symptomatic COVID-19, according to interim results from a phase 3 trial evaluating the treatment as a passive vaccine.

Vaccine 52

Vaccine Virus Research Laboratories Trials 52

The Pharma Data

NOVEMBER 16, 2020

The primary endpoint of the Phase 3 COVE study is based on the analysis of COVID-19 cases confirmed and adjudicated starting two weeks following the second dose of vaccine. All 11 cases occurred in the placebo group and none in the mRNA-1273 vaccinated group. The majority of adverse events were mild or moderate in severity.

Vaccine 52

Vaccine Clinical Trials FDA Disease 52

The Pharma Data

MARCH 14, 2023

QDENGA is the only dengue vaccine approved in Brazil for use in individuals regardless of previous exposure to dengue and without the need for pre-vaccination testing. QDENGA is the only dengue vaccine approved in Brazil for use in individuals regardless of previous exposure to dengue and without the need for pre-vaccination testing.

Vaccine 40

Vaccine Virus Hospitals Trials 40

The Pharma Data

FEBRUARY 23, 2022

Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) voted to recommend Pfizer’s TicoVac TM (tick-borne encephalitis (TBE) vaccine) for active immunization to prevent TBE in individuals 1 year of age and older, in the following U.S. Global President, Vaccines, Pfizer.

Vaccine 52

Vaccine FDA Approval Laboratories Virus 52

The Pharma Data

DECEMBER 10, 2020

Unsupervised use of this technique by people without medical training can lead to transmission of pathogens, according to Paul Carlson, principal investigator in the Laboratory of Mucosal Pathogens and Cellular Immunology at FDA’s Office of Vaccines Research and Review. 1, 2019, until effective screening methods are implemented.”.

FDA 52

FDA Laboratories RNA Virus 52

The Pharma Data

SEPTEMBER 14, 2020

Monoclonal antibodies, which are potent, laboratory-made antibodies, will be given to about 2,000 people to see if they are effective against coronavirus. Prof Martin Landray from the University of Oxford, who is co-leading the Recovery Trial, said: “This is the first type of treatment that’s targeted for this specific virus.

Trials 52

Trials Immune Response Virus Vaccine 52

The Pharma Data

NOVEMBER 16, 2020

Moderna announced this week that its coronavirus vaccine, mRNA-1273, appears to not only be more effective than Pfizer’s candidate but has significantly less stringent temperature requirements as well, likely making distribution and storage of the vaccine an easier, less daunting task. percent efficacy rate.

Vaccine 40

Vaccine Government Clinical Trials Disease 40

The Pharma Data

MARCH 16, 2021

The cobas SARS-CoV-2 Variant Set 1 Test is designed to detect key spike mutations in virus variants associated with increased human-to-human transmission. Among them, mutations E484K, N501Y and del 69-70 are located in the spike protein, the region that enables the virus to attach to and enter the human cell. 1.1.7), South Africa (B.1.351),

Clinical Trials 52

Clinical Trials Laboratories Virus Vaccine 52

The Pharma Data

NOVEMBER 29, 2021

1.1.529 a variant of concern, named Omicron, on the advice of WHO’s Technical Advisory Group on Virus Evolution (TAG-VE). Effectiveness of vaccines : WHO is working with technical partners to understand the potential impact of this variant on our existing countermeasures, including vaccines. Studies underway.

Vaccine 52

Vaccine Virus Disease Hospitals 52

PPD

OCTOBER 24, 2024

Hepatitis B virus (HBV) infection remains a significant public health challenge, particularly in low- and middle-income countries (LMIC) and in the Asia-Pacific region. This success is attributed to the integration of the HBV vaccine into the national immunization program.

Vaccine 52

Vaccine Virus Treatment Disease 52

The Pharma Data

MARCH 20, 2021

As laboratories around the world tackle the challenges of screening large numbers of samples for SARS-CoV-2, the managers of these labs have turned to the use of automation to address some key concerns. As there are fewer steps carried out by hand this reduces potential exposure for laboratory staff as well. In the examples below, we.

Laboratories 52

Laboratories Virus RNA Bioinformatics 52

The Pharma Data

DECEMBER 21, 2020

military scientists to determine if it might be resistant to vaccines. The team at the Walter Reed Army Institute of Research is checking genetic sequences of the mutated virus variant posted online by British researchers, CNN reported. of specimens testing positive at clinical laboratories last week, according to the U.S.

Vaccine 52

Vaccine Packaging Laboratories Virus 52

The Pharma Data

JANUARY 14, 2021

1.351 variants with a short turn-around time, ideal for retesting millions of positive samples to detect if the virus is the B.1.1.7 NovaType is already available as a Laboratory Developed Test (LDT) in Germany and will shortly be made available to the more than 50 Eurofins laboratories worldwide testing patients for COVID-19.

Laboratories 52

Laboratories Virus Vaccine FDA 52

Drug Target Review

JULY 17, 2024

While current polyclonal antibody (pAb) therapies are derived from plasma, GigaGen has developed single-cell discovery and development platforms to produce diverse and potent recombinant pAb therapies that are made in the laboratory.

Immune Response 59

Immune Response Therapies Laboratories Vaccine 59

The Pharma Data

JANUARY 26, 2021

Pre-clinical data showed the antibody can neutralize the virus by binding to an epitope on SARS-CoV-2 shared with SARS-CoV-1. As the virus continues to evolve, we, along with Lilly and GSK, share the view that we should pursue all possibilities to help end the pandemic and maximize the number of lives that can be saved.

Virus 52

Virus Trials Nurses Research Laboratories 52